Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the
Apr 26, 2021
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
Expanding upon an existing contract manufacturing deal first entered into in 2018; collaboration will further enable global manufacturing of ublituximab INCHEON, South Korea and NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Samsung Biologics (KRX: 207940.KS), the world’s leading contract development
Apr 26, 2021
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax
ULTRA-V Phase 2 trial has reached completion of patient enrollment NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the initiation of patient enrollment into the ULTRA-V Phase 3 randomized trial, evaluating the time-limited triple combination of
Apr 21, 2021
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab was generally well tolerated, with no unexpected safety signals BLA submission targeted in Q3 2021 Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET NEW
Apr 16, 2021
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of events for the upcoming American Academy of Neurology (AAN) Annual Meeting, being held virtually April 17 – 22, 2021.
Apr 15, 2021
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational
Mar 29, 2021
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory indolent
Mar 09, 2021
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been
Mar 04, 2021
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 – 10, 2021.
Mar 04, 2021
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
Conference call to be held today, Tuesday, March 2, 2021 at 8:30 AM ET NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2020 and recent company developments, along with a
Mar 02, 2021
Displaying 21 - 30 of 35